Characteristics | Immune Discordant Response Patients (n=28) |
Immune Concordant Response Patients (n=76) |
P values |
---|---|---|---|
Age (years) Mean (SD) Median (IQR) |
52 ± 14 (30-80) 49 (40-59) |
45 ±12 (18-71) 44 (36-52) |
0.03 |
Male [n (%)] | 17 (60) | 42 (55) | 0.66 |
Hemoglobin (g/dL) Mean (SD) Median (IQR) |
12.1 ± 2.3 (8-16) 12 (10-14) |
12.4 ± 2.1 (9-17) 12.5 (10.5-14) |
0.76 |
Platelet count (x109/L) Mean (SD) Median (IQR) |
265 ± 91 (140-490) 234 (197-317) |
256 ± 101 (170-686) 253 (202-299) |
0.68 |
CD4+ T cell count (cells/μL) Mean (SD) Median (IQR) |
10 6 ± 107 (30-343) 89 (13-164) |
350 ± 277 (90-1177) 271 (75-444) |
0.001 |
CD8+ T cell count (cells/μL) Mean (SD) Median (IQR) |
740 ± 674 (77-2780) 459 (347-923) |
996 ± 972 (78-7703) 849 (492-1120) |
0.19 |
CD4/CD8 ratio mean (SD) Median (IQR) |
0.31 ± 0.2 (0.07-0.7) 0.1 (0.04-0.25) |
0.46 ± 0.3 (0.1-1.19) 0.27 (0.12-0.51) |
0.04 |
CD19+ cell count (cells/μL) Mean (SD) Median (IQR) |
141 ± 138 (14-479) 95 (51-188) |
194 ± 184 (19-1042) 147 (66-257) |
0.17 |
CD56+ cell count (cells/μL) Mean (SD) Median (IQR) |
89 ± 73 (14-256) 67(32-119) |
185 ± 157 (10-996) 160(78-255) |
0.002 |
Co-infection with HCV [n (%)] | 5 (18) | 9 (12) | 0.42 |
HIV viral load (log10 copies/mL) Mean (SD) Median (IQR) |
4.2 ± 0.98 (2.6-6) 4.42 (3.5-4.8) |
4.1 ± 1.3 (2.6-6.9) 4.3 (2.6-5.1) |
0.35 |
Duration on ART (year) Mean (SD) Median (IQR) |
8 ± 3 (5-11) 8 (5-13) |
7.8 ± 3 (4-11) 8 (4-14) |
0.97 |
Efavirenz-based regimen [n (%)] | 22 (78) | 56 (73) | 0.79 |
AZT-3TC-based regimen [n (%)] | 16 (57) | 62 (81) | 0.02 |
Tuberculosis co-infection [n (%)] | 3 (10) | 6 (7) | 0.69 |